FiercePharma6h
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
MM&M14h
RFK Jr. confirmed as HHS Secretary: Here’s how pharma might be impacted
Vaccine policy, Medicare drug negotiations, and a potential DTC advertising ban will all fall under Kennedy’s purview as HHS ...
India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs
India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.
Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
Gesynta Pharma Receives $27 Million For Endometriosis Novel Therapy Drug
Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.
Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
JD Supra10h
Mintz IRA Update — The Future of the Medicare Drug Price Negotiation Program
The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...
GlobalData on MSN1d
Royalty Pharma pays $250m for rights to Biogen’s lupus drug
Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...
Attack drug costs
Recently, a letter to the editor I wrote was published in the Arkansas Democrat-Gazette on the subject of skyrocketing health-care costs, inclusive of rising pharmaceutical drug prices. I referenced ...